Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes
about
Renal effects of dapagliflozin in patients with type 2 diabetesRenal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of actionUpdate on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association.Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment.Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.Central obesity, type 2 diabetes and insulin: exploring a pathway full of thorns.Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.Canagliflozin (invokana), a novel oral agent for type-2 diabetes.Characteristics and Impact Factors of Renal Threshold for Glucose Excretion in Patients with Type 2 Diabetes Mellitus.Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes.Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.Long-term safety and efficacy of tofogliflozin add-on to insulin in patients with type 2 diabetes: results from a 52-week, multicenter, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS).Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus.Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy.
P2860
Q24564811-D82F495A-A146-4048-8893-2245DA5B12ADQ27027105-52DCC3A4-B8F9-4136-BDCC-7CFC6DAA9F74Q27687851-70A05B40-66B3-4F1E-952D-9D1035283C66Q33776230-E3274EEC-AD9B-4259-8959-07CC6458BE5AQ33837017-C0A361DA-1EF2-45F6-B15A-2801CDA0ED83Q35049845-13D1C0DA-1228-4C8E-9346-B8AF50640A1DQ35829203-36ADD7D6-02FD-49BC-985E-92EFBF57B2DEQ37351709-2BA79B41-0867-4F6C-8A27-2E506B2771A2Q37419399-F460BC39-84CC-4001-A950-941DE3401E23Q37677733-F50DF24C-BCA8-4E20-9145-5493881E4463Q38735470-A55B0E6D-2813-4DDB-90EB-5E689DE5231BQ47614541-0EF752A8-C968-4420-A483-348472392837Q48279607-4A570FCA-9571-4291-AA74-95A4EC9B22B4Q51744102-71311F10-BE7E-4724-98CD-598526D82C3FQ52598205-1827CEB3-2D1C-432E-825F-92B06342F408
P2860
Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Clinical potential of sodium-g ...... management of type 2 diabetes
@ast
Clinical potential of sodium-g ...... management of type 2 diabetes
@en
type
label
Clinical potential of sodium-g ...... management of type 2 diabetes
@ast
Clinical potential of sodium-g ...... management of type 2 diabetes
@en
prefLabel
Clinical potential of sodium-g ...... management of type 2 diabetes
@ast
Clinical potential of sodium-g ...... management of type 2 diabetes
@en
P2860
P356
P1476
Clinical potential of sodium-g ...... management of type 2 diabetes
@en
P2093
Ambika R Babu
Yoojin Kim
P2860
P304
P356
10.2147/DMSO.S22545
P577
2012-08-31T00:00:00Z